Abstract: A mixture of human milk oligosaccharides that consists essentially of 3?-O-sialyllactose, a component A which is either 3-O-fucosyllactose or lacto-N-tetraose, a component B which is 3-0-fucosyl-3?-O-sialyllactose when component A is 3-O-fucosyllactose and sialyllacto-N-tetraose a, when component A is lacto-N-tetraose and optionally lactose as a fourth component. The mixtures are made by treating 3?-O-sialyllactose and component A with an ?2,3-transsialidase. The mixtures are for use in anti-bacterial and anti-viral compositions, and for promoting the development of Bifidobacterium and Barnesiella.
Type:
Grant
Filed:
March 16, 2020
Date of Patent:
November 16, 2021
Assignee:
GLYCOM A/S
Inventors:
Elise Champion, Bruce McConnell, Gyula Dekany
Abstract: The application relates to a method for the prophylaxis or treatment of non-infectious diarrhea in a human, the method comprising administering to the human an effective amount of one or more human milk oligosaccharides.
Type:
Grant
Filed:
February 23, 2018
Date of Patent:
June 22, 2021
Assignee:
Glycom A/S
Inventors:
Bruce McConnell, Emma Elison, Louise Kristine Vigsnæs
Abstract: The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient a mixture comprising 2?-fucosyllactose (2?-FL) and lacto-N-neotetraose (LNnT).
Type:
Grant
Filed:
February 14, 2018
Date of Patent:
June 8, 2021
Assignee:
Glycom A/S
Inventors:
Thierry Hennet, Bruce McConnell, Emma Elison, Louise Kristine Vigsnæs
Abstract: The invention relates to HMOs and compositions comprising thereof for reducing the risk of, preventing, or treating CVD and/or CDV associated pathological conditions or diseases in humans, particularly in overweight and obese humans.
Type:
Grant
Filed:
June 15, 2016
Date of Patent:
April 27, 2021
Assignee:
Glycom A/S
Inventors:
Louise Kristine Vigsnæs, Bruce McConnell, Emma Elison
Abstract: The invention relates to a mixture of human milk oligosaccharides that consists essentially of: a) a component A which is 3-FL or DFL, a component B which is LNT, LNnT, LNFP-I or 2?-FL, a component C, which is LNFP-II when component B is LNT, or LNFP-III when component B is LNnT, or LNDFH-I when component B is LNFP-I, or DFL when component B is 2?-FL, and a component D, which is lactose when component A is 3-FL, or 2?-FL when component A is DFL, with the proviso that if component B is 2?-FL, then component A is 3-FL; or consists essentially of: b) 3-FL, a component E which is LNT, LNnT or LNFP-I, and a component F, which is LNFP-II when component E is LNT, or LNFP-III when component E is LNnT, or LNDFH-I when component E is LNFP-I, and to processes for producing them and their uses.
Type:
Grant
Filed:
June 10, 2019
Date of Patent:
March 16, 2021
Assignee:
GLYCOM A/S
Inventors:
Elise Champion, Bruce McConnell, Gyula Dekany
Abstract: The present invention relates to a method for separating sialylated oligosaccharides from a fermentation broth in which they are produced by a genetically modified microorganism The separation comprises the steps of: i) ultrafiltration; ii) nano-filtration; iii) optionally, activated charcoal treatment; and iv) treatment with strong anion and/or cation exchange resin.
Type:
Grant
Filed:
March 7, 2017
Date of Patent:
January 26, 2021
Assignee:
GLYCOM A/S
Inventors:
Martin Matwiejuk, Nikolay Khanzhin, Pierre Chassagne, Markus Jondelius Hederos
Abstract: The application relates to synthetic compositions and methods for preventing or reducing nociception and/or nociceptive sensitivity in a non-infant human The human is administered a composition comprising 6?-sialyllactose (6?-SL) and/or lacto-N-tetraose (LNT).
Type:
Application
Filed:
December 19, 2018
Publication date:
January 14, 2021
Applicant:
Glycom A/S
Inventors:
Bruce McCONNEIL, Louise Kristine VIGSNÆS, Sami DAMAK, Norbert SPRENGER, Francis FOATA
Abstract: The invention relates to a method for stabilising or reducing insulin resistance in patients having an obesity-related, metabolic disorder, the method comprising administering to the patient an effective amount of one or more human milk oligosaccharides (HMOs).
Type:
Grant
Filed:
June 15, 2016
Date of Patent:
January 5, 2021
Assignee:
GLYCOM A/S
Inventors:
Bruce McConnell, Louise Kristine Vigsnæs, Emma Elison
Abstract: The invention relates to a synthetic composition comprising human milk oligosaccharides for use in at least partially restoring the commensal gastrointestinal microbiota and preventing or mitigating antibiotic associated diarrhoea.
Type:
Grant
Filed:
November 17, 2016
Date of Patent:
December 15, 2020
Assignee:
GLYCOM A/S
Inventors:
Bruce McConnell, Louise Kristine Vigsnæs, David Paul Kronlage
Abstract: This invention relates to a method and composition for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation.
Type:
Grant
Filed:
February 24, 2017
Date of Patent:
December 8, 2020
Assignee:
GLYCOM A/S
Inventors:
Bruce McConnell, Louise Kristine Vigsnæs
Abstract: A synthetic composition for use in improving one or more co-morbid mental disorder symptoms of a patient with IBS, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.
Type:
Grant
Filed:
October 28, 2016
Date of Patent:
November 17, 2020
Assignee:
GLYCOM A/S
Inventors:
Bruce McConnell, Emma Elison, Louise Kristine Vigsnæs
Abstract: The application relates to synthetic compositions containing one or more human milk oligosaccharides for regulating satiety or reducing propensity to obesity.
Type:
Grant
Filed:
June 15, 2016
Date of Patent:
November 17, 2020
Assignee:
GLYCOM A/S
Inventors:
Louise Kristine Vigsnæs, Bruce McConnell, Emma Elison
Abstract: The invention relates to a microbial production of recombinant oligosaccharides, particularly of human milk oligosaccharides (HMOs), using a genetically modified microorganism, particularly E. coli, in antibiotic-free cultivating medium.
Type:
Grant
Filed:
December 19, 2016
Date of Patent:
November 10, 2020
Assignee:
GLYCOM A/S
Inventors:
Manos Papadakis, Margit Pedersen, Katrine Bych
Abstract: The invention relates to a synthetic composition comprising one or more human milk monosaccharides and/or one or more human milk oligosaccharides for use in reducing intestinal permeability, endotoxemia and/or low-grade inflammation in patients with metabolic disorders.
Type:
Grant
Filed:
December 8, 2015
Date of Patent:
November 10, 2020
Assignee:
GLYCOM A/S
Inventors:
Emma Salomonsson, Bruce McConnell, Thierry Hennet, Louise Kristine Vigsnæs
Abstract: The present invention relates to the isolation and purification of sialylated oligosaccharides from an aqueous medium in which they are produced.
Type:
Grant
Filed:
September 13, 2017
Date of Patent:
October 13, 2020
Assignee:
GLYCOM A/S
Inventors:
Martin Matwiejuk, Markus Jondelius Hederos
Abstract: A synthetic composition for use in treating or improving one or more emotion and/or mood disorders in a patient, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.
Type:
Grant
Filed:
October 28, 2016
Date of Patent:
September 22, 2020
Assignee:
GLYCOM A/S
Inventors:
Bruce McConnell, Emma Elison, Louise Kristine Vigsnæs
Abstract: A human milk oligosaccharide (HMO) or a synthetic composition comprising said HMO, for use in increasing the abundance, particularly the relative abundance, of a Bifidobacterium of the B. adolescentis phylogenic group in the microbiota in the gastro-intestinal tract of a human, preferably a non-infant human. The HMO(s) and/or synthetic composition is useful in; increasing particularly the relative abundance of B. adolescentis and/or B. pseudocatenulatum; for treating or preventing in said non-infant human with type 2 diabetes and/or obesity; an enteropathogenic infection; impaired gut barrier function and/or; an inflammation related to gastro intestinal condition, preferably irritable bowel disease (IBD) or irritable bowel syndrome (IBS); as a nutritional composition. The HMO is a fucosylated neutral HMO, a non-fucosylated neutral HMO, or a mixture of a fucosylated and a non-fucosylated neutral HMO.
Type:
Grant
Filed:
September 14, 2016
Date of Patent:
August 25, 2020
Assignee:
GLYCOM A/S
Inventors:
Louise Kristine Vigsnæs, Bruce McConnell
Abstract: The invention relates to a genetically modified microorganism for making a recombinant oligosaccharide, preferably of 3-8 monosaccharide units, more preferably of 3-5 monosaccharide units, particularly a HMO, which comprises one or more genes encoding a sucrose utilization system, so the microorganism can use sucrose as a carbon and energy source. The one or more genes encoding a sucrose utilization system are preferably one or more genes encoding a heterologous PTS-dependent sucrose utilization transport system, such as the scr genes.
Type:
Grant
Filed:
June 29, 2015
Date of Patent:
August 4, 2020
Assignee:
GLYCOM A/S
Inventors:
Eric Samain, Pauline Peltier-Pain, Katrine Bych, Ted Johanson, Elise Champion, Gyula Dekany